Arca Biopharma, Inc.

Amgen Fremont Inc.

Nuvelo, Inc.

Teva Pharmaceuticals Australia Pty Ltd

Wouter Korver

Larry L Green

Adam Clarke

Matthew Pollard

Sarah Lee Pogue

Glen Eugene Mikesell

Arie Abo

Sirid-Aimee Kellermann

Tetsuya Taura

Sirid-Aimée Kellermann

Stephen Tran

Jack Tzu Chiao Lin

Jr David S Wilson

Antony G Doyle

Anti-NTB-A antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind NTB-A and treat diseases, such as hematologic malignancies, which are characterized by expression of NIB-A.

Antibodies to NTB-A

The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included.

Methods of monitoring a human anti-human antibody response and inhibitors thereof

Anti-CLL-1 antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind CLL-1 and treat diseases, such as hematologic malignancies, which are characterized by expression of CLL-1.

Antibodies to CLL-1

The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included. Some embodiments herein are directed to transgenic mouse embodiments relevant for HAHA responses.

Reducing the risk of human anti-human antibodies through V gene manipulation

Anti-NTB-A antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind NTB-A and treat diseases, such as hematologic malignancies, which are characterized by expression of NTB-A.

Determining the risk of human anti-human antibodies in transgenic mice

Growing community of inventors

Menlo Park, CA, United States of America

Wouter Korver